If you would like further information or have questions or comments, please contact:

John Lacey, MS, MBA
Head of Investor Relations & Corporate Communications

Potential life-changing treatments are on the way

Each molecule in our development pipeline is carefully selected for its potential ability to improve upon the standard of care, delivering maximum value to patients